A carregar...

Targeted therapeutic options and future perspectives for HER2-positive breast cancer

Over the past 2 decades, there has been an extraordinary progress in the regimens developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) are commonly recommended anti-HER2 target...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Signal Transduct Target Ther
Main Authors: Wang, Jiani, Xu, Binghe
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6799843/
https://ncbi.nlm.nih.gov/pubmed/31637013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-019-0069-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!